^
Association details:
| Biomarker: | HDAC5 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer
Published date:
01/08/2021
Excerpt:
HDAC5 loss also conferred resistance to CDK4/6 inhibitors such as Palbociclib in prostate and breast cancer cells in vitro and prostate tumors in vivo, but this effect was overcome by the BET-CBP/p300 dual inhibitor NEO2734.
DOI:
10.1158/0008-5472.CAN-20-2828
